The US Food and Drug Administration (FDA) officially approved Moderna’s mRNA flu vaccine for market on August 5. This is the world’s first approved influenza vaccine using mRNA technology platform, marking another major breakthrough in infectious disease prevention following COVID-19 vaccines. The development process was fraught with delays and technical challenges.

Event Details

The vaccine, designated mRNA-1010, uses Moderna’s signature lipid nanoparticle delivery system to encode influenza hemagglutinin proteins and trigger immune responses. The FDA’s approval was based on Phase III clinical trial data showing superior immunogenicity in elderly populations compared to traditional inactivated vaccines.

The approval process was far from smooth. In 2024, the FDA’s initial review requested additional safety data, delaying market entry by nearly two years. Moderna invested over $800 million in additional research and development during this period, ultimately convincing regulators of its risk-benefit profile.

The vaccine’s greatest technical advantage is its short production cycle. Traditional flu vaccines require six months of egg cultivation, while mRNA vaccines need only about 60 days from sequence determination to finished product. This means when influenza strains mutate, the mRNA platform can respond faster, significantly improving vaccine-strain matching.

Panoramic Perspective

This vaccine’s approval holds strategic significance for the entire mRNA technology platform. During the COVID pandemic, mRNA technology demonstrated its rapid response capability in public health emergencies, but as the pandemic receded, the industry questioned whether the technology could expand to other disease areas. The flu vaccine’s approval dispelled such doubts, paving the way for mRNA applications in respiratory syncytial virus, malaria, and even cancer vaccines.

From an industry competition perspective, this breakthrough will intensify vaccine market restructuring. Traditional vaccine giants like Pfizer and Sanofi face generational challenges in technology pathways. Pfizer is also developing an mRNA flu vaccine currently in Phase III trials; Moderna’s first-to-market approval will force competitors to accelerate their R&D pace.

The deeper impact lies in public health strategy transformation. Influenza causes 290,000 to 650,000 deaths globally each year, with vaccination being the most effective prevention. mRNA technology’s efficiency and customizability could boost flu vaccination rates, particularly in high-variation years when vaccine strains poorly match circulating strains.

Multiple Perspectives

Supporting View: The FDA Commissioner stated in a declaration that this approval reflects regulatory support for innovative science, with the mRNA platform providing more flexible tools for combating seasonal influenza. Moderna CEO Stéphane Bancel called it the culmination of the company’s decade-long technology accumulation.

Skeptical View: Some public health experts remain cautious about mRNA vaccines’ long-term safety. A Harvard infectious disease modeling expert noted that while short-term clinical data is encouraging, real-world effectiveness of mRNA vaccines in the influenza context requires three to five years of post-market surveillance data.

Industry Reaction: Wall Street reacted positively, with Moderna shares rising 12% in after-hours trading. Analysts generally believe the flu vaccine market, valued at approximately $4 billion annually, could see Moderna capture 20% market share within three years.

Edited by: GoodInfo Global News Team